Dimerix Activates First Clinical Trial Site in Japan, Secures Milestone Payment

An update from Dimerix Limited ( (AU:DXB) ) is now available.

Dimerix Limited has announced the activation of its first clinical trial site in Japan for the ACTION3 Phase 3 clinical trial, which has triggered a milestone payment of ¥400 million from its Japanese partner, FUSO Pharmaceutical Industries Ltd. This development marks a significant step in Dimerix’s global clinical program for DMX-200, aimed at treating patients with FSGS, and underscores the company’s strategic partnerships and market expansion efforts in Japan. FUSO will handle clinical development costs and regulatory submissions in Japan, while Dimerix continues to focus on global trial delivery and licensing opportunities.

The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.

More about Dimerix Limited

Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, including kidney diseases. The company is advancing its proprietary product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease, utilizing its Receptor Heteromer Investigation Technology (Receptor-HIT) platform.

Average Trading Volume: 3,263,715

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$355.1M

See more data about DXB stock on TipRanks’ Stock Analysis page.